Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA

(AZN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
03/12/2019 03/13/2019 03/14/2019 03/15/2019 03/18/2019 Date
6283(c) 6293(c) 6309(c) 6274(c) 6350(c) Last
2 089 813 1 650 333 3 425 670 9 737 384 1 262 164 Volume
-0.51% +0.16% +0.25% -0.55% +1.21% Change
More quotes
Financials (USD)
Sales 2019 23 497 M
EBIT 2019 6 147 M
Net income 2019 2 810 M
Debt 2019 14 089 M
Yield 2019 3,34%
Sales 2020 25 890 M
EBIT 2020 7 468 M
Net income 2020 4 102 M
Debt 2020 14 020 M
Yield 2020 3,37%
P/E ratio 2019 37,73
P/E ratio 2020 26,57
EV / Sales2019 5,10x
EV / Sales2020 4,62x
Capitalization 106 B
More Financials
Company
AstraZeneca is one of the world's leading pharmaceutical groups. Net sales break down by treatment area as follows: - cardiovascular and metabolic diseases (32.3%); - respiratory diseases (20.9%); - oncology (17.9%); - other (18.5%): inflammatory and autoimmune diseases, neurological diseases,... 
Sector
Pharmaceuticals
Calendar
03/31 | 02:00pmPresentation
More about the company
Surperformance© ratings of AstraZeneca
Trading Rating : Investor Rating :
More Ratings
Latest news on ASTRAZENECA
09:36aASTRAZENECA : Farxiga Trial Shows Reduction of Heart Problems in 16% of Patients
DJ
09:10aASTRAZENECA : First sub-analyses from the DECLARE-TIMI 58 trial further support ..
PU
09:09aASTRAZENECA : First Sub-Analyses from the DECLARE-TIMI 58 Trial Further Support ..
BU
03:24aASTRAZENECA : Gets Orphan Drug Designation for Lung Disease Treatment
DJ
03:21aASTRAZENECA : US FDA grants saracatinib Orphan Drug Designation for idiopathic p..
PU
03:01aASTRAZENECA : US FDA grants saracatinib ODD for IPF
AQ
03/14ASTRAZENECA : showcases next-generation Oncology pipeline addressing unmet patie..
PU
03/12BioNTech hires banks for IPO worth up to $800 million - sources
RE
03/12EUROPE MARKETS: European Markets Mixed As Investors Wait For Vote On Revised ..
DJ
03/11LONDON MARKETS: London Markets Climb; Mining Shares Boost FTSE 100
DJ
More news
Analyst Recommendations on ASTRAZENECA
More recommendations
Sector news : Pharmaceuticals - NEC
12:34pEXCLUSIVE : Sanofi says working on CEO succession plan
RE
12:07pSANOFI : Working on CEO Succession Plan -Reuters
DJ
10:43aGLOBAL MARKETS LIVE : ING, Boeing, GM, Worldpay…
03:00aNOVARTIS : Alcon Acquires PowerVision for $285 Million
DJ
03/15UK shares up after vote for Brexit delay; oil majors gain
RE
More sector news : Pharmaceuticals - NEC
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 84,6 $
Spread / Average Target 1,5%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Shriti Vadera Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA6.83%105 661
JOHNSON & JOHNSON6.63%366 397
NOVARTIS11.61%238 367
ROCHE HOLDING LTD.11.61%233 055
PFIZER-4.28%231 954
MERCK AND COMPANY6.75%210 550